The Clinical Study Of Ginkgo Biloba Extract EGb761 In The Treatment Of Mild Vascular Cognitive Impairment

Objective To investigate the clinical effect of ginkgo biloba extract EGb761(EGb761)on patients with mild vascular cognitive impairment(mVCI).Methods 100 mVCI patients was selected by Mini-mental State Examination(MMSE),Montreal cognitive assessment scale(MoCA)and Hamilton depression rating scale(HAMD)and Hamilton anxiety scale(HAMA)from May 2017 to November 2018 in third people's hospital of Bengbu neurology hospital.The patients were divided into the treatment group(standard treatment for cerebral apoplexy+EGb761)and the control group(standard treatment for cerebral apoplexy)with 50 cases each randomly.MMSE,MoCA,HAMD and HAMA,Trail Making Test A/B(TMT-A/B),Boston naming test-2(BNT-2),Auditory verb learn test-Huashan version(AVLT-H),Clock Drawing Test(CDT),instrumental Activities of daily living(IADL),Neuropsychiatric questionnaire(NPI),NIH Stroke Scale(NIHss),modified Rankin scale(MRS)of the two groups was followed up for 1 year,and was interviewed once every 4 months for a total of 4 times.The scale score changes at each phase of treatment follow-up were compared and analyzed.Results Before treatment,there was no significant difference between the treatment group and the control group in terms of gender,age,education,course of disease,severity of disease and other baseline data(P>0.05).After treatment 4 months,the MMSE,MoCA,CDT,IADL,BNT-2,AVLT-H immediate recall rating scale of treatment groups were significantly increased respectively compared with before treatment(P<0.01).The MMSE,MoCA,CDT,IADL,BNT-2,AVLT-H immediate recall rating scale of control groups were higher than that of before treatment(P<0.05).The MMSE,MoCA,CDT,IADL,BNT-2,AVLT-H immediate recall rating scale of treatment group were significantly higher than that of control group respectively(P<0.05).After 4 months of treatment,the TMT-A/B,NIHss,MRS score of treatment groups was significantly lower than that before treatment respectively(P<0.01),while the TMT-A/B,NIHss,MRS score of control groups were higher than that of before treatment(P<0.05).The TMT-A/B,NIHss,MRS score of the treatment group was significantly lower than that of the control group respectively(P<0.05).8 months after treatment,the scores of MMSE,MoCA,CDT,IADL,BNT-2 rating scale in the treatment group were significantly increased compared with 4 months treatment(P<0.05).However,there was no significant change in the control group for the scores of MMSE,MoCA,CDT,IADL,BNT-2 rating scale compared with 4 months treatment(P>0.05).The MMSE,MoCA,CDT,IADL,BNT-2 scale score in the treatment group was significantly higher than that in the control group(P<0.05).After 8 months of treatment,the AVLT-H recall scale scores in both groups showed no significant changes compared with 4 months treatment(P>0.05).After 8 months treatment,the TMT-A/B scale scores of both groups were significantly lower than those of 4 months treatment(P<0.05),while the TMT-A/B scale scores of the treatment group were significantly lower than those of the control group(P<0.05).After 8 months treatment,the scores of NIHss and MRS scale in the treatment group were significantly lower than those of 4 months treatment(P<0.05),while the scores of NIHss and MRS scale in the control group were not significantly different from those of 4 months treatment(P>0.05).The scores of NIHss and MRS scale in the treatment group were significantly lower than those in the control group(P<0.05).After 12 months of treatment,the TMT-A/B scores of the two groups were significantly lower than those 8 months after treatment(P<0.05).Compared with 8 months after treatment,CDT scores of the two groups were significantly increased than those 8 months after treatment(P<0.05).There was no significant changes for the MMSE,MoCA,bnt-2,IADL,NIHss,MRS and AVLT-H immediate recall scale scores of the two groups compared with 8 months after treatment(P>0.05).There was no significant changes for the HAMA,HAMD and NPI scores of the two groups compared with those before treatment,4,8 and 12 months of treatment(P>0.05).Conclusions Ginkgo biloba extract EGB761 can improve the overall cognitive function of mVCI patients,with the most significant improvement in attention,execution,visuospatial,language and transient memory functions.Moreover,EGB761 can promote the neurological function recovery of VCI patients and improve their instrumental daily living ability.However,it had no obvious effect on the mental state of mVCI patients.EGB761 has high safety and can be used as an ideal treatment for mVCI patients.